Department of Biomedical Engineering, University of Texas, Austin, TX 78712, USA.
McKetta Department of Chemical Engineering, University of Texas, Austin, TX 78712, USA.
J Control Release. 2021 Jan 10;329:1162-1171. doi: 10.1016/j.jconrel.2020.10.045. Epub 2020 Oct 27.
Nanoparticles must recognize, adhere to, and/or traverse multiple barriers in sequence to achieve cytosolic drug delivery. New nanoparticles often exhibit a unique ability to cross a single barrier (i.e. the vasculature, cell membrane, or endosomal compartment), but fail to deliver an adequate dose to intracellular sites of action because they cannot traverse other biological barriers for which they were not optimized. Here, we developed poly(acrylamide-co-methacrylic acid) nanogels that were modified in a modular manner with bioactive peptides. This nanogel does not recognize target cells or disrupt endosomal vesicles in its unmodified state, but can incorporate peptides with molecular recognition or environmentally responsive properties. Nanogels were modified with up to 15 wt% peptide without significantly altering their size, surface charge, or stability in aqueous buffer. Nanogels modified with a colon cancer-targeting oligopeptide exhibited up to a 324% enhancement in co-localization with SW-48 colon cancer cells in vitro, while influencing nanogel uptake by fibroblasts and macrophages to a lesser extent. Nanogels modified with an endosome disrupting peptide failed to retain its native endosomolytic activity, when coupled either individually or in combination with the targeting peptide. Our results offer a proof-of-concept for modifying synthetic nanogels with a combination of peptides that address barriers to cytosolic delivery individually and in tandem. Our data further motivate the need to identify endosome disrupting moieties which retain their activity within poly(acidic) networks.
纳米颗粒必须依次识别、黏附和/或穿透多个屏障,才能实现细胞质内的药物递送。新的纳米颗粒通常表现出独特的穿越单个屏障(即血管、细胞膜或内体隔室)的能力,但由于无法穿透其他未优化的生物屏障,无法将足够的药物剂量递送到细胞内作用部位。在这里,我们开发了聚(丙烯酰胺-co-甲基丙烯酸)纳米凝胶,它以模块化的方式用生物活性肽进行了修饰。在未修饰的状态下,这种纳米凝胶不会识别靶细胞或破坏内体囊泡,但可以结合具有分子识别或环境响应特性的肽。纳米凝胶的修饰量最高可达 15wt%,而不会显著改变其尺寸、表面电荷或在水性缓冲液中的稳定性。用结肠癌靶向寡肽修饰的纳米凝胶在体外与 SW-48 结肠癌细胞的共定位增加了 324%,而对成纤维细胞和巨噬细胞的纳米凝胶摄取的影响较小。当与靶向肽单独或组合使用时,修饰有破坏内体肽的纳米凝胶未能保留其天然的溶酶体活性。我们的结果为用单独和串联解决细胞质递送至的屏障的肽来修饰合成纳米凝胶提供了概念验证。我们的数据进一步证明了需要确定在聚(酸性)网络内保留其活性的内体破坏部分。